Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00335738 · OUTCOME

Pathological Features Present At Diagnosis - Anterior Chamber Seeding (ACS)

Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma · Source last updated 2021-02-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of patients with ACS
Interval / dispersion
95% Confidence Interval
Time frame
At enrollment

What was measured

Proportion of patients who had anterior chamber seeding at enrollment.

Analysis population: Central review of the biological materials for this aim was available on only 313 patients. This outcome measure is calculated by combing all groups as characterized in the Patient Flow.

Groups in this outcome

All Patients

This outcome measure is calculated by combining all groups as defined in the trials record.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients313

Reported measurements

Source class 1
Values in Proportion of patients with ACS · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients0.045Not reported0.0250.074Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.025
        upper Limit
        0.074
        value
        0.045
denoms
  1. counts
    1. group Id
      OG000
      value
      313
    units
    Participants
description
Proportion of patients who had anterior chamber seeding at enrollment.
dispersion Type
95% Confidence Interval
groups
  1. description
    This outcome measure is calculated by combining all groups as defined in the trials record.
    id
    OG000
    title
    All Patients
param Type
NUMBER
population Description
Central review of the biological materials for this aim was available on only 313 patients. This outcome measure is calculated by combing all groups as characterized in the Patient Flow.
reporting Status
POSTED
time Frame
At enrollment
title
Pathological Features Present At Diagnosis - Anterior Chamber Seeding (ACS)
type
SECONDARY
unit Of Measure
Proportion of patients with ACS

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice